ATE406172T1 - Verwendung von löslichem cd14 zur behandlung von erkrankungen - Google Patents

Verwendung von löslichem cd14 zur behandlung von erkrankungen

Info

Publication number
ATE406172T1
ATE406172T1 AT04713556T AT04713556T ATE406172T1 AT E406172 T1 ATE406172 T1 AT E406172T1 AT 04713556 T AT04713556 T AT 04713556T AT 04713556 T AT04713556 T AT 04713556T AT E406172 T1 ATE406172 T1 AT E406172T1
Authority
AT
Austria
Prior art keywords
soluble
treat diseases
disease
ovaric
scd14
Prior art date
Application number
AT04713556T
Other languages
English (en)
Inventor
Jose Fernandez-Real
Engel Wilfredo Ricart
Original Assignee
Bridge Biores Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200300665A external-priority patent/ES2232273B1/es
Application filed by Bridge Biores Ltd filed Critical Bridge Biores Ltd
Application granted granted Critical
Publication of ATE406172T1 publication Critical patent/ATE406172T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04713556T 2003-03-21 2004-02-23 Verwendung von löslichem cd14 zur behandlung von erkrankungen ATE406172T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200300665A ES2232273B1 (es) 2003-03-21 2003-03-21 Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
EP03104722 2003-12-16

Publications (1)

Publication Number Publication Date
ATE406172T1 true ATE406172T1 (de) 2008-09-15

Family

ID=33031271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04713556T ATE406172T1 (de) 2003-03-21 2004-02-23 Verwendung von löslichem cd14 zur behandlung von erkrankungen

Country Status (6)

Country Link
US (1) US7655237B2 (de)
EP (1) EP1608396B1 (de)
AT (1) ATE406172T1 (de)
DE (1) DE602004016128D1 (de)
ES (1) ES2312966T3 (de)
WO (1) WO2004082578A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095916A2 (en) * 2008-01-29 2009-08-06 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Cd14 and peptides thereof for protection of cells against cell death

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029227A1 (de) 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
WO1994008609A1 (en) * 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
AUPO295696A0 (en) * 1996-10-09 1996-11-07 Berrigan, Thomas John Drug delivery means
DK1158989T3 (da) 1999-03-09 2007-10-22 Anker Stefan Anvendelse af inhibitorer af endotoksin til behandling af kakeksi

Also Published As

Publication number Publication date
WO2004082578A2 (en) 2004-09-30
WO2004082578A3 (en) 2005-08-04
EP1608396A2 (de) 2005-12-28
US7655237B2 (en) 2010-02-02
DE602004016128D1 (de) 2008-10-09
EP1608396B1 (de) 2008-08-27
ES2312966T3 (es) 2009-03-01
US20070172477A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
Mottalib et al. Weight management in patients with type 1 diabetes and obesity
EA200501420A1 (ru) Устройство доставки для лекарственной и клеточной терапии
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
AR047779A1 (es) Composiciones y metodos para tratar diabetes
UA83854C2 (uk) Застосування телмісартану для підвищення чутливості до інсуліну
NO20073456L (no) Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling
NZ594044A (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
BR9906813A (pt) Método para administração de insulina aspb28- humana
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
BRPI0206432A2 (pt) métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
EP1543158A4 (de) Regulierte aptamer-therapeutika
Weisbord Symptoms and their correlates in chronic kidney disease
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
ATE406172T1 (de) Verwendung von löslichem cd14 zur behandlung von erkrankungen
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
DE602004022968D1 (de) Ie behandlung mti insulinsensibilisatoren
CY1116171T1 (el) Χρηση ακετυλο-l-καρνιτινης για την παρασκευη φαρμακου για τη θεραπευτικη αγωγη του νευροπαθητικου πονου σε διαβητικους ασθενεις
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
NZ513087A (en) Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
DE502004011874D1 (de) Flupirtine-präparat zur behandlung von neurodegeneetes mellitus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties